nct_id
stringlengths 11
11
| nlm_download_date_description
float64 | study_first_submitted_date
stringlengths 10
10
| results_first_submitted_date
stringlengths 10
10
⌀ | disposition_first_submitted_date
stringclasses 493
values | last_update_submitted_date
stringlengths 10
10
| study_first_submitted_qc_date
stringlengths 10
10
| study_first_posted_date
stringlengths 10
10
| study_first_posted_date_type
stringclasses 2
values | results_first_submitted_qc_date
stringlengths 10
10
⌀ | results_first_posted_date
stringlengths 10
10
⌀ | results_first_posted_date_type
stringclasses 2
values | disposition_first_submitted_qc_date
stringclasses 321
values | disposition_first_posted_date
stringclasses 478
values | disposition_first_posted_date_type
stringclasses 2
values | last_update_submitted_qc_date
stringlengths 10
10
| last_update_posted_date
stringlengths 10
10
| last_update_posted_date_type
stringclasses 2
values | start_month_year
stringlengths 7
10
⌀ | start_date_type
stringclasses 2
values | start_date
stringlengths 10
10
⌀ | verification_month_year
stringclasses 151
values | verification_date
stringclasses 151
values | completion_month_year
stringlengths 7
10
| completion_date_type
stringclasses 2
values | completion_date
stringlengths 10
10
| primary_completion_month_year
stringlengths 7
10
| primary_completion_date_type
stringclasses 2
values | primary_completion_date
stringlengths 10
10
| target_duration
float64 | study_type
stringclasses 1
value | acronym
stringlengths 2
14
⌀ | baseline_population
stringlengths 2
501
⌀ | brief_title
stringlengths 18
300
| official_title
stringlengths 28
563
⌀ | overall_status
stringclasses 4
values | last_known_status
float64 | phase
stringclasses 7
values | enrollment
float64 0
477k
| enrollment_type
stringclasses 2
values | source
stringlengths 3
107
| limitations_and_caveats
stringlengths 10
503
⌀ | number_of_arms
float64 1
27
⌀ | number_of_groups
float64 | why_stopped
stringlengths 3
252
⌀ | has_expanded_access
stringclasses 2
values | expanded_access_type_individual
float64 | expanded_access_type_intermediate
float64 | expanded_access_type_treatment
float64 | has_dmc
stringclasses 2
values | is_fda_regulated_drug
stringclasses 2
values | is_fda_regulated_device
stringclasses 2
values | is_unapproved_device
stringclasses 1
value | is_ppsd
float64 | is_us_export
stringclasses 2
values | biospec_retention
float64 | biospec_description
float64 | ipd_time_frame
stringclasses 442
values | ipd_access_criteria
stringclasses 465
values | ipd_url
stringclasses 124
values | plan_to_share_ipd
stringclasses 3
values | plan_to_share_ipd_description
stringlengths 3
998
⌀ | created_at
stringclasses 526
values | updated_at
stringclasses 526
values | source_class
stringclasses 8
values | delayed_posting
float64 | expanded_access_nctid
stringclasses 80
values | expanded_access_status_for_nctid
stringclasses 4
values | fdaaa801_violation
float64 | baseline_type_units_analyzed
stringclasses 11
values | patient_registry
float64 | completion_year
int64 2.02k
2.02k
| labels
float64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT03012581 | null | 2017-01-02 | null | null | 2024-02-26 | 2017-01-04 | 2017-01-06 | ESTIMATED | null | null | null | null | null | null | 2024-02-26 | 2024-02-28 | ACTUAL | 2017-06-16 | ACTUAL | 2017-06-16 | 2024-02 | 2024-02-29 | 2023-11-11 | ACTUAL | 2023-11-11 | 2022-12-22 | ACTUAL | 2022-12-22 | null | INTERVENTIONAL | AcSé | null | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types | COMPLETED | null | PHASE2 | 269 | ACTUAL | UNICANCER | null | 1 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 05:34:40.88875 | 2024-10-16 05:34:40.88875 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT02032784 | null | 2014-01-08 | null | null | 2020-07-15 | 2014-01-08 | 2014-01-10 | ESTIMATED | null | null | null | null | null | null | 2020-07-15 | 2020-07-16 | ACTUAL | 2014-03 | null | 2014-03-31 | 2020-07 | 2020-07-31 | 2020-07-06 | ACTUAL | 2020-07-06 | 2018-06-28 | ACTUAL | 2018-06-28 | null | INTERVENTIONAL | null | null | Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding | Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding | TERMINATED | null | PHASE4 | 33 | ACTUAL | AdventHealth | null | 2 | null | Difficult to enroll subjects | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT05064800 | null | 2021-09-01 | 2022-10-18 | null | 2023-10-02 | 2021-09-22 | 2021-10-01 | ACTUAL | 2023-10-02 | 2024-03-29 | ACTUAL | null | null | null | 2023-10-02 | 2024-03-29 | ACTUAL | 2021-09-21 | ACTUAL | 2021-09-21 | 2023-10 | 2023-10-31 | 2021-12-06 | ACTUAL | 2021-12-06 | 2021-12-06 | ACTUAL | 2021-12-06 | null | INTERVENTIONAL | null | All participants who were enrolled in the study. | PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants | A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS | COMPLETED | null | PHASE1 | 24 | ACTUAL | Pfizer | null | 3 | null | null | null | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT02047318 | null | 2014-01-23 | 2021-03-29 | null | 2021-11-17 | 2014-01-24 | 2014-01-28 | ESTIMATED | 2021-11-17 | 2021-11-19 | ACTUAL | null | null | null | 2021-11-17 | 2021-11-19 | ACTUAL | 2013-12-20 | ACTUAL | 2013-12-20 | 2021-11 | 2021-11-30 | 2020-06-17 | ACTUAL | 2020-06-17 | 2020-06-17 | ACTUAL | 2020-06-17 | null | INTERVENTIONAL | IMAGINE | After a short dose escalation period, participants received MRX 280 ug/kg/day, which consisted of most of their exposure within the study. As such, summaries are presented as a single arm, MRX. | An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) | A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001 Also Known as Maralixibat (MRX), an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome | COMPLETED | null | PHASE2 | 19 | ACTUAL | Mirum Pharmaceuticals, Inc. | Limitations of the trial such as small numbers of subjects analyzed or technical problems leading to unreliable data. | 1 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT05347147 | null | 2022-04-20 | 2024-02-01 | null | 2024-03-26 | 2022-04-20 | 2022-04-26 | ACTUAL | 2024-03-26 | 2024-04-24 | ACTUAL | null | null | null | 2024-03-26 | 2024-04-24 | ACTUAL | 2022-11-18 | ACTUAL | 2022-11-18 | 2024-03 | 2024-03-31 | 2023-10-20 | ACTUAL | 2023-10-20 | 2023-09-18 | ACTUAL | 2023-09-18 | null | INTERVENTIONAL | IIH EVOLVE | null | A Trial to Determine the Efficacy and Safety of Presendin in IIH | A Phase III Randomised, Placebo-controlled, Double-blind, Multi-centre, Clinical Trial to Determine the Efficacy and Safety of Presendin in Idiopathic Intracranial Hypertension | TERMINATED | null | PHASE3 | 14 | ACTUAL | Invex Therapeutics Ltd. | Due to the early termination of the study, planned analyses were not fully conducted but were restricted to the most relevant safety endpoints as per the abbreviated SAP v1. Outcome measure (efficacy) data are raw data from individual subjects, with minimal analysis; e.g., where an outcome measure specified change from baseline to Week 24, baseline and Week 24 values are presented. Efficacy data were not subject to the same verification as safety data and no efficacy conclusions should be drawn. | 2 | null | Following a strategic evaluation of its IIH EVOLVE Phase III clinical trial investigating Presendin™, the Invex Board has made the difficult decision that the continuation of the trial is not viable and therefore the trial has been terminated. | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT04839575 | null | 2021-04-07 | null | null | 2024-08-01 | 2021-04-07 | 2021-04-09 | ACTUAL | null | null | null | null | null | null | 2024-08-01 | 2024-08-05 | ACTUAL | 2021-04-06 | ACTUAL | 2021-04-06 | 2023-07 | 2023-07-31 | 2022-12-19 | ACTUAL | 2022-12-19 | 2022-12-19 | ACTUAL | 2022-12-19 | null | INTERVENTIONAL | null | null | Study of Latiglutenase in T1D/CD Patients | Prospective, Double-Blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of Latiglutenase Treatment in Type 1 Diabetes Patients With Celiac Disease While Undergoing Periodic Gluten Exposure | TERMINATED | null | PHASE2 | 13 | ACTUAL | Entero Therapeutics | null | 2 | null | Covid-19 interruptions and enrollment challenges | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04575597 | null | 2020-09-30 | 2023-04-26 | null | 2023-06-05 | 2020-10-02 | 2020-10-05 | ACTUAL | 2023-06-05 | 2023-06-28 | ACTUAL | null | null | null | 2023-06-05 | 2023-06-28 | ACTUAL | 2020-10-19 | ACTUAL | 2020-10-19 | 2023-05 | 2023-05-31 | 2022-05-05 | ACTUAL | 2022-05-05 | 2022-05-05 | ACTUAL | 2022-05-05 | null | INTERVENTIONAL | null | null | Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) | A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19. | COMPLETED | null | PHASE2/PHASE3 | 1,735 | ACTUAL | Merck Sharp & Dohme LLC | null | 6 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | http://engagezone.msd.com/ds_documentation.php | YES | http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT04518995 | null | 2020-08-16 | 2023-04-07 | null | 2023-04-07 | 2020-08-16 | 2020-08-19 | ACTUAL | 2023-04-07 | 2023-05-03 | ACTUAL | null | null | null | 2023-04-07 | 2023-05-03 | ACTUAL | 2020-11-23 | ACTUAL | 2020-11-23 | 2023-04 | 2023-04-30 | 2022-04-19 | ACTUAL | 2022-04-19 | 2022-04-19 | ACTUAL | 2022-04-19 | null | INTERVENTIONAL | THRIVE-AA1 | All randomized participants included all participants who were randomized in the study. | Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1) | COMPLETED | null | PHASE3 | 706 | ACTUAL | Concert Pharmaceuticals | null | 3 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT04136444 | null | 2019-10-21 | 2021-05-28 | null | 2021-07-08 | 2019-10-21 | 2019-10-23 | ACTUAL | 2021-07-08 | 2021-07-28 | ACTUAL | null | null | null | 2021-07-08 | 2021-07-28 | ACTUAL | 2019-10-28 | ACTUAL | 2019-10-28 | 2021-07 | 2021-07-31 | 2020-05-22 | ACTUAL | 2020-05-22 | 2020-05-22 | ACTUAL | 2020-05-22 | null | INTERVENTIONAL | null | Baseline Characteristics refer to the Safety Set (SS) which consisted of all study participants who received at least 1 dose of the investigational medicinal product (IMP). | A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function | An Open-Label, Parallel-Group, Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal Hepatic Function or With Moderately Impaired Hepatic Function (Child-Pugh Class B) | TERMINATED | null | PHASE1 | 12 | ACTUAL | UCB Pharma | null | 2 | null | Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | NO | Due to the small sample size in this trial, Individual Patient Data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared. | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT04976257 | null | 2021-07-14 | null | null | 2023-04-05 | 2021-07-14 | 2021-07-26 | ACTUAL | null | null | null | null | null | null | 2023-04-05 | 2023-04-07 | ACTUAL | 2021-10-13 | ACTUAL | 2021-10-13 | 2023-04 | 2023-04-30 | 2023-03-22 | ACTUAL | 2023-03-22 | 2023-03-22 | ACTUAL | 2023-03-22 | null | INTERVENTIONAL | null | null | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion | Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA Radioligand Infusions in Treatment-Naïve Prostate Cancer Patients | COMPLETED | null | EARLY_PHASE1 | 5 | ACTUAL | University of California, San Francisco | null | 1 | null | null | null | null | null | null | t | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT04625972 | null | 2020-11-10 | 2022-04-06 | null | 2023-11-17 | 2020-11-10 | 2020-11-12 | ACTUAL | 2022-10-24 | 2022-10-25 | ACTUAL | null | null | null | 2023-11-17 | 2023-11-21 | ACTUAL | 2020-12-02 | ACTUAL | 2020-12-02 | 2023-11 | 2023-11-30 | 2022-07-25 | ACTUAL | 2022-07-25 | 2021-04-07 | ACTUAL | 2021-04-07 | null | INTERVENTIONAL | STORM CHASER | Full Analysis Set | Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults | A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19 | COMPLETED | null | PHASE3 | 1,131 | ACTUAL | AstraZeneca | Results are reported for the Primary analysis conducted during the study. | 2 | null | null | f | null | null | null | t | t | f | null | null | t | null | null | AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure | When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure | https://astrazenecagroup-dt.pharmacm.com/DT/Home | YES | Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure | 2024-10-17 03:02:07.507684 | 2024-10-17 03:02:07.507684 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT04705844 | null | 2021-01-10 | null | null | 2022-03-02 | 2021-01-10 | 2021-01-12 | ACTUAL | null | null | null | null | null | null | 2022-03-02 | 2022-03-03 | ACTUAL | 2021-09 | ESTIMATED | 2021-09-30 | 2022-03 | 2022-03-31 | 2022-09 | ESTIMATED | 2022-09-30 | 2022-09 | ESTIMATED | 2022-09-30 | null | INTERVENTIONAL | COMBAAT | null | Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT) | Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Adalimumab (Humira) or Placebo in Patients With Mild-Moderate COVID-19 | WITHDRAWN | null | PHASE3 | 0 | ACTUAL | Resilience Government Services, Inc. | null | 2 | null | study withdrawn prior to screening subjects | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT03355482 | null | 2017-11-22 | null | null | 2024-02-16 | 2017-11-22 | 2017-11-28 | ACTUAL | null | null | null | null | null | null | 2024-02-16 | 2024-02-20 | ACTUAL | 2017-04-10 | ACTUAL | 2017-04-10 | 2024-02 | 2024-02-29 | 2022-12-16 | ACTUAL | 2022-12-16 | 2022-02-16 | ACTUAL | 2022-02-16 | null | INTERVENTIONAL | MEASURE | null | MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE | MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE | TERMINATED | null | PHASE2 | 9 | ACTUAL | Oklahoma Medical Research Foundation | null | 2 | null | poor recruitment, funding | null | null | null | null | f | t | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT03591770 | null | 2018-07-09 | null | null | 2024-07-04 | 2018-07-09 | 2018-07-19 | ACTUAL | null | null | null | null | null | null | 2024-07-04 | 2024-07-08 | ACTUAL | 2019-07-31 | ACTUAL | 2019-07-31 | 2024-07 | 2024-07-31 | 2024-07-04 | ACTUAL | 2024-07-04 | 2024-07-04 | ACTUAL | 2024-07-04 | null | INTERVENTIONAL | null | null | Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib | The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib | TERMINATED | null | PHASE4 | 15 | ACTUAL | Boston Medical Center | null | 4 | null | Unable to recruit adequate numbers of participants to answer the research question. | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT03859973 | null | 2019-02-25 | 2023-10-30 | 2023-04-24 | 2023-10-30 | 2019-02-28 | 2019-03-01 | ACTUAL | 2023-10-30 | 2023-11-18 | ACTUAL | null | 2023-04-25 | ACTUAL | 2023-10-30 | 2023-11-18 | ACTUAL | 2019-04-15 | ACTUAL | 2019-04-15 | 2023-10 | 2023-10-31 | 2022-11-04 | ACTUAL | 2022-11-04 | 2022-09-30 | ACTUAL | 2022-09-30 | null | INTERVENTIONAL | null | Treated Set (TS) includes all patients in randomized set (RS) who were treated with at least 1 dose of the trial regimen (including both trial drug and computerized cognitive training (CCT)). | This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia | A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period in Patients With Schizophrenia | COMPLETED | null | PHASE2 | 200 | ACTUAL | Boehringer Ingelheim | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication. | For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'. | https://www.mystudywindow.com/msw/datasharing | YES | After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement.~Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.~The data shared are the raw clinical study data sets. | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT04301310 | null | 2020-03-06 | null | null | 2022-03-17 | 2020-03-06 | 2020-03-10 | ACTUAL | null | null | null | null | null | null | 2022-03-17 | 2022-03-31 | ACTUAL | 2020-03-09 | ACTUAL | 2020-03-09 | 2022-03 | 2022-03-31 | 2020-03-16 | ACTUAL | 2020-03-16 | 2020-03-16 | ACTUAL | 2020-03-16 | null | INTERVENTIONAL | null | null | Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants | A Phase 1, Open-label Study to Evaluate the Effect of Rifampin on the Single Dose Pharmacokinetics, Safety, and Tolerability of BMS-986235 in Healthy Participants | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Bristol-Myers Squibb | null | 1 | null | Business objectives have changed | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT04395950 | null | 2020-05-15 | null | null | 2021-08-19 | 2020-05-19 | 2020-05-20 | ACTUAL | null | null | null | null | null | null | 2021-08-19 | 2021-08-25 | ACTUAL | 2020-12 | ESTIMATED | 2020-12-31 | 2021-08 | 2021-08-31 | 2021-08-19 | ACTUAL | 2021-08-19 | 2021-08-19 | ACTUAL | 2021-08-19 | null | INTERVENTIONAL | null | null | Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism | A Phase 1B, Single-Blinded, Linear Two Period, Placebo-controlled Study to Evaluate the Effects of 10 mg/Day of PF-05221304, Liver Targeted Acetyl-CoA Carboxylase Inhibitor (ACCi) on Very Low Density Lipoprotein ApoB100 and TG Secretion | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Columbia University | null | 2 | null | Poor enrollment | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03259308 | null | 2017-08-21 | 2021-03-26 | null | 2021-03-26 | 2017-08-21 | 2017-08-23 | ACTUAL | 2021-03-26 | 2021-04-26 | ACTUAL | null | null | null | 2021-03-26 | 2021-04-26 | ACTUAL | 2017-12-05 | ACTUAL | 2017-12-05 | 2021-03 | 2021-03-31 | 2020-10-06 | ACTUAL | 2020-10-06 | 2020-07-15 | ACTUAL | 2020-07-15 | null | INTERVENTIONAL | FIGARO UC 302 | Safety set consisted of all participants who had received at least 1 dose of investigational product. | Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis | A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302) | TERMINATED | null | PHASE3 | 279 | ACTUAL | Takeda | The study was terminated as per the sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early. | 3 | null | Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT04987944 | null | 2021-07-26 | 2024-02-02 | null | 2024-02-02 | 2021-07-26 | 2021-08-03 | ACTUAL | 2024-02-02 | 2024-07-19 | ACTUAL | null | null | null | 2024-02-02 | 2024-07-19 | ACTUAL | 2021-10-18 | ACTUAL | 2021-10-18 | 2024-02 | 2024-02-29 | 2023-04-04 | ACTUAL | 2023-04-04 | 2023-03-29 | ACTUAL | 2023-03-29 | null | INTERVENTIONAL | null | Safety analysis set included all randomized participants who received at least 1 dose of study therapy. | Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma | A Phase 1b, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Safety and Efficacy of Oral Zavegepant in Subjects With Mild Allergic Asthma | TERMINATED | null | PHASE1 | 45 | ACTUAL | Pfizer | null | 2 | null | Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns. | f | null | null | null | null | f | f | null | null | null | null | null | null | null | null | NO | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-15 06:57:07.762525 | 2024-10-15 06:57:07.762525 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT05161936 | null | 2021-12-08 | 2024-02-11 | null | 2024-05-20 | 2021-12-08 | 2021-12-17 | ACTUAL | 2024-05-20 | 2024-05-22 | ACTUAL | null | null | null | 2024-05-20 | 2024-05-22 | ACTUAL | 2022-01-27 | ACTUAL | 2022-01-27 | 2024-04 | 2024-04-30 | 2022-11-01 | ACTUAL | 2022-11-01 | 2022-11-01 | ACTUAL | 2022-11-01 | null | INTERVENTIONAL | null | No participants were enrolled or treated with Lumasiran Dose 2. | A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels | TERMINATED | null | PHASE2 | 2 | ACTUAL | Alnylam Pharmaceuticals | null | 3 | null | Study terminated early due to low enrollment | f | null | null | null | null | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04082676 | null | 2019-09-01 | null | null | 2022-03-08 | 2019-09-06 | 2019-09-09 | ACTUAL | null | null | null | null | null | null | 2022-03-08 | 2022-03-22 | ACTUAL | 2019-11-30 | ACTUAL | 2019-11-30 | 2022-03 | 2022-03-31 | 2021-09-01 | ACTUAL | 2021-09-01 | 2021-09-01 | ACTUAL | 2021-09-01 | null | INTERVENTIONAL | null | null | Height Versus Height and Weight Based Spinal Bupivacaine on Maternal Haemodynamics for Elective Cesarean in Short Stature Patients | Effect of Height Versus Height and Weight Based Intrathecal Bupivacaine Dose on Maternal Haemodynamics for Elective Caesarean Section in Short Stature Patients: A Randomized Trial | COMPLETED | null | PHASE4 | 112 | ACTUAL | B.P. Koirala Institute of Health Sciences | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | The final research data and study protocol will be shared with the journal accepting the article for publication. It will be available simultaneously after publication of the article. | The IPD link will be accessed from the link provided in the published manuscript. The IPD may also be available to other researchers by the investigators upon request. | https://data.mendeley.com/ | YES | The final research data will be stored in Mendeley. The final data will be released and shared during the publication process of the manuscript. | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT02974426 | null | 2016-11-20 | null | null | 2024-06-10 | 2016-11-22 | 2016-11-28 | ESTIMATED | null | null | null | null | null | null | 2024-06-10 | 2024-06-12 | ACTUAL | 2016-11 | null | 2016-11-30 | 2024-06 | 2024-06-30 | 2024-02 | ACTUAL | 2024-02-29 | 2024-02 | ACTUAL | 2024-02-29 | null | INTERVENTIONAL | null | null | To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer | Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer | TERMINATED | null | PHASE3 | 132 | ACTUAL | Shanghai Chest Hospital | null | 2 | null | Enrollment was delayed and the number of eligible patients significantly declined with the use of neoadjuvant or adjuvant ICIs and TKIs therapies. Thus, this trial was closed due to insufficient accrual. | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT02923921 | null | 2016-09-30 | 2020-08-14 | null | 2020-09-24 | 2016-10-03 | 2016-10-05 | ESTIMATED | 2020-09-24 | 2020-10-19 | ACTUAL | null | null | null | 2020-09-24 | 2020-10-19 | ACTUAL | 2017-03-01 | ACTUAL | 2017-03-01 | 2020-04-15 | 2020-04-15 | 2020-03-05 | ACTUAL | 2020-03-05 | 2019-09-09 | ACTUAL | 2019-09-09 | null | INTERVENTIONAL | Sequoia | All randomized participants. | Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer | Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen | COMPLETED | null | PHASE3 | 567 | ACTUAL | Eli Lilly and Company | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting. | A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement. | http://www.clinicalstudydatarequest.com | YES | Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement. | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT03342859 | null | 2017-10-26 | null | null | 2021-01-05 | 2017-11-10 | 2017-11-17 | ACTUAL | null | null | null | null | null | null | 2021-01-05 | 2021-01-06 | ACTUAL | 2017-11-16 | ACTUAL | 2017-11-16 | 2021-01 | 2021-01-31 | 2020-01-13 | ACTUAL | 2020-01-13 | 2018-12-17 | ACTUAL | 2018-12-17 | null | INTERVENTIONAL | null | null | Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned | An Open-label, Parallel Group, Multi-center Study to Investigate Pharmacodynamic Effects After Daily Administration of Vilaprisan or Ulipristal Acetate for 8-12 Weeks in Patients With Uterine Fibroids for Whom Surgery (Hysterectomy or Myomectomy) is Planned | TERMINATED | null | PHASE1 | 10 | ACTUAL | Bayer | null | 3 | null | Due to findings in the preclinical carcinogenicity studies for vilaprisan (BAY1002670) | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT03934307 | null | 2019-04-29 | null | null | 2023-01-13 | 2019-04-29 | 2019-05-01 | ACTUAL | null | null | null | null | null | null | 2023-01-13 | 2023-01-17 | ACTUAL | 2019-05-01 | ACTUAL | 2019-05-01 | 2023-01 | 2023-01-31 | 2023-01-04 | ACTUAL | 2023-01-04 | 2022-04-20 | ACTUAL | 2022-04-20 | null | INTERVENTIONAL | null | null | A Study to Evaluate ALN-AGT01 in Patients With Hypertension | A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Dose and Active Comparator-Controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-AGT01 in Patients With Hypertension | COMPLETED | null | PHASE1 | 124 | ACTUAL | Alnylam Pharmaceuticals | null | 7 | null | null | f | null | null | null | null | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT03336866 | null | 2017-11-06 | 2021-10-20 | null | 2022-02-11 | 2017-11-06 | 2017-11-08 | ACTUAL | 2022-02-11 | 2022-03-10 | ACTUAL | null | null | null | 2022-02-11 | 2022-03-10 | ACTUAL | 2018-05-03 | ACTUAL | 2018-05-03 | 2022-01 | 2022-01-31 | 2021-03-09 | ACTUAL | 2021-03-09 | 2020-11-23 | ACTUAL | 2020-11-23 | null | INTERVENTIONAL | STAMPOUT | null | Study of Antibody for Methamphetamine Outpatient Therapy | STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy | COMPLETED | null | PHASE1/PHASE2 | 77 | ACTUAL | InterveXion Therapeutics, LLC | All participants were dosed with methamphetamine on a weekly basis following treatment with IXT-m200 or placebo. Thus, safety of IXT-m200 alone cannot be distinguished from the expected adverse events resulting from the methamphetamine doses. Variability of the responses on the drug effects questionnaires was much higher than anticipated. This resulted in insufficient power to detect differences between treated and control groups. | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | These datasets will be available for distribution following submission to the FDA of the Clinical Study Report and publication. They will be available for 2 years after the initial publication. | These datasets and associated documentation will be made available on CD by the Sponsor to requestors under a data sharing agreement that provides for: (1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology and not distributing to third parties; and (3) a commitment to destroying or returning the data after analyses are completed. Requests should be sent to intervexion@gmail.com. | null | YES | Final datasets are expected to contain pharmacokinetic data on IXT-m200 and METH, subjective effects data, immunogenicity totals, and safety data. No individually identifiable private information will be distributed. | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT04374552 | null | 2020-05-02 | null | null | 2020-10-29 | 2020-05-02 | 2020-05-05 | ACTUAL | null | null | null | null | null | null | 2020-10-29 | 2020-11-02 | ACTUAL | 2020-05-05 | ESTIMATED | 2020-05-05 | 2020-05 | 2020-05-31 | 2021-04 | ESTIMATED | 2021-04-30 | 2020-11 | ESTIMATED | 2020-11-30 | null | INTERVENTIONAL | ACT | null | Asymptomatic COVID-19 Trial | RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Rutgers, The State University of New Jersey | null | 2 | null | The investigators have decided not to go forward with this protocol | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT01734928 | null | 2012-11-23 | 2023-05-09 | null | 2023-06-05 | 2012-11-27 | 2012-11-28 | ESTIMATED | 2023-06-05 | 2023-06-06 | ACTUAL | null | null | null | 2023-06-05 | 2023-06-06 | ACTUAL | 2013-01-07 | ACTUAL | 2013-01-07 | 2023-05 | 2023-05-31 | 2022-05-13 | ACTUAL | 2022-05-13 | 2022-05-09 | ACTUAL | 2022-05-09 | null | INTERVENTIONAL | OPTIMISMM | null | Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | COMPLETED | null | PHASE3 | 559 | ACTUAL | Celgene | null | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT02427178 | null | 2015-02-10 | null | null | 2022-07-28 | 2015-04-22 | 2015-04-27 | ESTIMATED | null | null | null | null | null | null | 2022-07-28 | 2022-08-01 | ACTUAL | 2015-03 | ESTIMATED | 2015-03-31 | 2022-07 | 2022-07-31 | 2023-06 | ESTIMATED | 2023-06-30 | 2022-06 | ESTIMATED | 2022-06-30 | null | INTERVENTIONAL | MASS | null | MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study | MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy) AHSCT (Allogeneic Hematopoietic Stem Cell Transplant) Safety Study | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Columbia University | null | 1 | null | Poor enrollment | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | YES | When applicable, we will submit a manuscript describing the results | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT04131192 | null | 2019-10-10 | null | null | 2022-05-04 | 2019-10-16 | 2019-10-18 | ACTUAL | null | null | null | null | null | null | 2022-05-04 | 2022-05-06 | ACTUAL | 2019-11-11 | ACTUAL | 2019-11-11 | 2022-05 | 2022-05-31 | 2021-09-09 | ACTUAL | 2021-09-09 | 2021-09-09 | ACTUAL | 2021-09-09 | null | INTERVENTIONAL | null | null | Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer | A Phase Ib, Multi-center, Open-label Study of Z650 and Gemcitabine in Advanced Pancreatic Cancer | TERMINATED | null | PHASE1 | 13 | ACTUAL | Sunshine Lake Pharma Co., Ltd. | null | 1 | null | Combined with the analysis of the existing data of the trial, there was no obvious advantage compared with the clinical standard treatments, and the clinical trial was decided to be terminated based on the benefit of the subjects. | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04133922 | null | 2019-10-15 | null | null | 2022-03-07 | 2019-10-17 | 2019-10-21 | ACTUAL | null | null | null | null | null | null | 2022-03-07 | 2022-03-22 | ACTUAL | 2019-10-14 | ACTUAL | 2019-10-14 | 2022-03 | 2022-03-31 | 2024-10 | ESTIMATED | 2024-10-31 | 2023-10 | ESTIMATED | 2023-10-31 | null | INTERVENTIONAL | KML001 | null | Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes | Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes | WITHDRAWN | null | EARLY_PHASE1 | 0 | ACTUAL | University of Virginia | null | 3 | null | the study drug could not be obtained | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT05665647 | null | 2022-12-19 | null | null | 2023-02-19 | 2022-12-19 | 2022-12-27 | ACTUAL | null | null | null | null | null | null | 2023-02-19 | 2023-02-21 | ACTUAL | 2022-12-29 | ACTUAL | 2022-12-29 | 2023-01 | 2023-01-31 | 2023-02-14 | ACTUAL | 2023-02-14 | 2023-01-26 | ACTUAL | 2023-01-26 | null | INTERVENTIONAL | null | null | Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants | An Open Labe Study to Evaluate the Drug-Drug Interaction of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Adult Chinese Participants | COMPLETED | null | PHASE1 | 36 | ACTUAL | Jiangsu Simcere Pharmaceutical Co., Ltd. | null | 3 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT02965976 | null | 2016-11-15 | 2023-01-23 | null | 2023-01-23 | 2016-11-15 | 2016-11-17 | ESTIMATED | 2023-01-23 | 2023-02-16 | ACTUAL | null | null | null | 2023-01-23 | 2023-02-16 | ACTUAL | 2016-12-30 | ACTUAL | 2016-12-30 | 2023-01 | 2023-01-31 | 2022-04-28 | ACTUAL | 2022-04-28 | 2022-01-28 | ACTUAL | 2022-01-28 | null | INTERVENTIONAL | null | null | Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer | Double-Arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II) | COMPLETED | null | PHASE2 | 33 | ACTUAL | Roswell Park Cancer Institute | null | 2 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | OTHER | null | null | null | null | null | null | 2,022 | 1 |
NCT04521946 | null | 2020-08-18 | null | null | 2023-10-02 | 2020-08-18 | 2020-08-21 | ACTUAL | null | null | null | null | null | null | 2023-10-02 | 2023-10-04 | ACTUAL | 2021-01-14 | ACTUAL | 2021-01-14 | 2023-10 | 2023-10-31 | 2022-12-20 | ACTUAL | 2022-12-20 | 2022-12-20 | ACTUAL | 2022-12-20 | null | INTERVENTIONAL | null | null | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | A Pilot Study of Allogeneic Hematopoietic Cell Transplantation for Patients With High Grade Central Nervous System Malignancies | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | M.D. Anderson Cancer Center | null | 1 | null | No participants enrolled. | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT02931110 | null | 2016-06-06 | null | null | 2020-12-08 | 2016-10-11 | 2016-10-12 | ESTIMATED | null | null | null | null | null | null | 2020-12-08 | 2020-12-10 | ACTUAL | 2017-01 | ACTUAL | 2017-01-31 | 2020-12 | 2020-12-31 | 2020-10 | ACTUAL | 2020-10-31 | 2020-10 | ACTUAL | 2020-10-31 | null | INTERVENTIONAL | null | null | Study of IV CBL0137 in Previously Treated Hematological Subjects | A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers | TERMINATED | null | PHASE1 | 5 | ACTUAL | Incuron | null | 1 | null | Business reasons | f | null | null | null | f | null | null | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT04338997 | null | 2020-04-03 | null | null | 2020-12-02 | 2020-04-07 | 2020-04-08 | ACTUAL | null | null | null | null | null | null | 2020-12-02 | 2020-12-04 | ACTUAL | 2020-10 | ESTIMATED | 2020-10-31 | 2020-09 | 2020-09-30 | 2020-12 | ESTIMATED | 2020-12-31 | 2020-11 | ESTIMATED | 2020-11-30 | null | INTERVENTIONAL | null | null | PK Study in Patients With Parkinson's Disease With IZD174 | An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Inflazome UK Ltd | null | 1 | null | Strategic decision by Sponsor | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT03191201 | null | 2017-05-17 | null | null | 2020-03-24 | 2017-06-15 | 2017-06-19 | ACTUAL | null | null | null | null | null | null | 2020-03-24 | 2020-03-26 | ACTUAL | 2017-06-21 | ACTUAL | 2017-06-21 | 2020-03 | 2020-03-31 | 2020-03-09 | ACTUAL | 2020-03-09 | 2020-03-09 | ACTUAL | 2020-03-09 | null | INTERVENTIONAL | DIAFER | null | A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis. | A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age. | TERMINATED | null | PHASE4 | 32 | ACTUAL | University of Lausanne | null | 2 | null | The reason for early termination is difficulties recruiting that caused a premature ending of financial resources ensuring protected time for research. | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 03:08:40.171445 | 2024-10-17 03:08:40.171445 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT04210245 | null | 2019-12-16 | null | null | 2023-06-09 | 2019-12-20 | 2019-12-24 | ACTUAL | null | null | null | null | null | null | 2023-06-09 | 2023-06-13 | ACTUAL | 2020-03-23 | ACTUAL | 2020-03-23 | 2023-06 | 2023-06-30 | 2023-02-23 | ACTUAL | 2023-02-23 | 2023-01-04 | ACTUAL | 2023-01-04 | null | INTERVENTIONAL | null | null | Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) | Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4) | COMPLETED | null | PHASE2 | 160 | ACTUAL | NGM Biopharmaceuticals, Inc | null | 4 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,023 | 1 |
NCT01208051 | null | 2010-09-22 | 2021-03-22 | null | 2021-06-24 | 2010-09-22 | 2010-09-23 | ESTIMATED | 2021-06-24 | 2021-07-15 | ACTUAL | null | null | null | 2021-06-24 | 2021-07-15 | ACTUAL | 2010-09-09 | ACTUAL | 2010-09-09 | 2021-06 | 2021-06-30 | 2020-02-01 | ACTUAL | 2020-02-01 | 2020-02-01 | ACTUAL | 2020-02-01 | null | INTERVENTIONAL | null | null | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer | COMPLETED | null | PHASE1/PHASE2 | 127 | ACTUAL | National Cancer Institute (NCI) | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | NIH | null | null | null | null | null | null | 2,020 | 1 |
NCT02295722 | null | 2014-10-30 | null | null | 2024-07-04 | 2014-11-18 | 2014-11-20 | ESTIMATED | null | null | null | null | null | null | 2024-07-04 | 2024-07-08 | ACTUAL | 2015-04 | null | 2015-04-30 | 2024-07 | 2024-07-31 | 2023-02 | ACTUAL | 2023-02-28 | 2023-02 | ACTUAL | 2023-02-28 | null | INTERVENTIONAL | GEMHDM2014 | null | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma | Infusional Gemcitabine and High-dose Melphalan (HDM) Conditioning Prior to (ASCT) Autologous Stem Cell Transplantation for Patients With Relapsed/Refractory Lymphoma | TERMINATED | null | PHASE1/PHASE2 | 100 | ACTUAL | AHS Cancer Control Alberta | null | 1 | null | It did not show a significant benefit to justify completing the full target accrual. | f | null | null | null | f | null | null | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 05:34:40.88875 | 2024-10-16 05:34:40.88875 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT03331562 | null | 2017-10-18 | 2021-11-09 | null | 2022-12-01 | 2017-10-31 | 2017-11-06 | ACTUAL | 2022-12-01 | 2022-12-27 | ACTUAL | null | null | null | 2022-12-01 | 2022-12-27 | ACTUAL | 2017-12-27 | ACTUAL | 2017-12-27 | 2022-12 | 2022-12-31 | 2020-07-10 | ACTUAL | 2020-07-10 | 2020-06-29 | ACTUAL | 2020-06-29 | null | INTERVENTIONAL | null | null | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response | COMPLETED | null | PHASE2 | 24 | ACTUAL | Translational Genomics Research Institute | Due to lack of grant funding, the other exploratory objectives to assess the changes in tumor and/or tissue texture on imaging, and to monitor and compare gut microbial communities in both arms, have not yet been able to be accomplished. The Investigators are looking for some way to fund the exploratory objectives in the future. | 2 | null | null | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT04243837 | null | 2020-01-21 | 2024-01-30 | 2023-09-07 | 2024-03-26 | 2020-01-24 | 2020-01-28 | ACTUAL | 2024-03-26 | 2024-04-23 | ACTUAL | null | 2024-04-23 | ACTUAL | 2024-03-26 | 2024-04-23 | ACTUAL | 2020-03-01 | ACTUAL | 2020-03-01 | 2022-04 | 2022-04-30 | 2022-09-09 | ACTUAL | 2022-09-09 | 2022-09-09 | ACTUAL | 2022-09-09 | null | INTERVENTIONAL | null | null | LYT-100 in Patients With BCRL | A Phase 2a Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of Deupirfenidone (LYT-100) in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema | TERMINATED | null | PHASE2 | 50 | ACTUAL | PureTech | null | 2 | null | Primary objective/endpoint has been established, will not pursue development of the disease indication further | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT03134638 | null | 2017-04-19 | null | null | 2021-03-05 | 2017-04-25 | 2017-05-01 | ACTUAL | null | null | null | null | null | null | 2021-03-05 | 2021-03-09 | ACTUAL | 2017-05-12 | ACTUAL | 2017-05-12 | 2019-11 | 2019-11-30 | 2020-06-24 | ACTUAL | 2020-06-24 | 2020-05-15 | ACTUAL | 2020-05-15 | null | INTERVENTIONAL | null | null | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors | TERMINATED | null | PHASE1 | 107 | ACTUAL | Syros Pharmaceuticals | null | 6 | null | Business Decision | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT03434366 | null | 2018-01-28 | null | null | 2022-04-05 | 2018-02-09 | 2018-02-15 | ACTUAL | null | null | null | null | null | null | 2022-04-05 | 2022-04-12 | ACTUAL | 2018-01-20 | ACTUAL | 2018-01-20 | 2022-04 | 2022-04-30 | 2023-12-30 | ESTIMATED | 2023-12-30 | 2023-12-30 | ESTIMATED | 2023-12-30 | null | INTERVENTIONAL | null | null | Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder | Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder | SUSPENDED | null | PHASE2 | 50 | ESTIMATED | Guangzhou Women and Children's Medical Center | null | 3 | null | The effects are not good | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT03312907 | null | 2017-10-13 | 2022-03-25 | 2020-12-01 | 2022-03-25 | 2017-10-13 | 2017-10-18 | ACTUAL | 2022-03-25 | 2022-04-25 | ACTUAL | 2020-12-01 | 2020-12-08 | ACTUAL | 2022-03-25 | 2022-04-25 | ACTUAL | 2018-03-01 | ACTUAL | 2018-03-01 | 2022-02 | 2022-02-28 | 2021-07-07 | ACTUAL | 2021-07-07 | 2020-05-29 | ACTUAL | 2020-05-29 | null | INTERVENTIONAL | null | Baseline characteristics were presented for Intent-to-Treat Population. | A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) | COMPLETED | null | PHASE3 | 292 | ACTUAL | GlaxoSmithKline | null | 3 | null | null | t | null | null | null | t | t | f | null | null | null | null | null | IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study. | Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months. | http://clinicalstudydatarequest.com | YES | IPD for this study will be made available via the Clinical Study Data Request site. | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | NCT03125486 | NO_LONGER_AVAILABLE | null | null | null | 2,021 | 1 |
NCT04130802 | null | 2019-10-16 | 2022-02-17 | 2021-01-13 | 2023-01-13 | 2019-10-16 | 2019-10-17 | ACTUAL | 2022-02-17 | 2022-03-15 | ACTUAL | 2021-01-13 | 2021-01-15 | ACTUAL | 2023-01-13 | 2023-01-17 | ACTUAL | 2019-09-27 | ACTUAL | 2019-09-27 | 2021-01 | 2021-01-31 | 2020-01-31 | ACTUAL | 2020-01-31 | 2020-01-31 | ACTUAL | 2020-01-31 | null | INTERVENTIONAL | SKYGGN | null | OCS-01 in Treating Inflammation and Pain in Post-cataract Patients | A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of Two Doses of OCS 01 Compared to Vehicle in the Treatment of Inflammation and Pain Following Cataract Surgery | COMPLETED | null | PHASE2 | 153 | ACTUAL | Oculis | null | 3 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 05:34:40.88875 | 2024-10-16 05:34:40.88875 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT02541903 | null | 2015-08-24 | 2020-03-03 | null | 2020-04-10 | 2015-09-03 | 2015-09-04 | ESTIMATED | 2020-04-10 | 2020-04-14 | ACTUAL | null | null | null | 2020-04-10 | 2020-04-14 | ACTUAL | 2015-10 | null | 2015-10-31 | 2020-04 | 2020-04-30 | 2020-04 | ACTUAL | 2020-04-30 | 2019-01-26 | ACTUAL | 2019-01-26 | null | INTERVENTIONAL | null | 1 patient expired after signing consent but before starting treatment | Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma | A Phase 2 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Following Systemic Therapy | TERMINATED | null | PHASE2 | 8 | ACTUAL | University of Alabama at Birmingham | This study was closed early due to poor enrollment. | 1 | null | poor overall accrual | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03083041 | null | 2017-03-02 | null | null | 2023-02-02 | 2017-03-13 | 2017-03-17 | ACTUAL | null | null | null | null | null | null | 2023-02-02 | 2023-02-03 | ACTUAL | 2017-03-22 | ACTUAL | 2017-03-22 | 2022-06 | 2022-06-30 | 2022-05-20 | ACTUAL | 2022-05-20 | 2022-04-22 | ACTUAL | 2022-04-22 | null | INTERVENTIONAL | null | null | A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) | A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung | COMPLETED | null | PHASE2 | 210 | ACTUAL | Jiangsu HengRui Medicine Co., Ltd. | null | 3 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT04381988 | null | 2020-05-08 | 2021-10-25 | null | 2021-10-25 | 2020-05-08 | 2020-05-11 | ACTUAL | 2021-10-25 | 2021-10-27 | ACTUAL | null | null | null | 2021-10-25 | 2021-10-27 | ACTUAL | 2020-05-07 | ACTUAL | 2020-05-07 | 2021-04 | 2021-04-30 | 2021-04-21 | ACTUAL | 2021-04-21 | 2021-04-21 | ACTUAL | 2021-04-21 | null | INTERVENTIONAL | null | The study was terminated before more participants were accrued. | A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy | A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID) | TERMINATED | null | PHASE2 | 4 | ACTUAL | Memorial Sloan Kettering Cancer Center | null | 2 | null | The study was terminated based results of other studies and use of the new vaccine. | f | null | null | null | null | t | f | null | null | f | null | null | null | null | null | YES | Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org. | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT01750281 | null | 2012-12-12 | 2017-01-13 | null | 2023-10-12 | 2012-12-13 | 2012-12-17 | ESTIMATED | 2017-06-21 | 2017-07-19 | ACTUAL | null | null | null | 2023-10-12 | 2023-10-24 | ACTUAL | 2012-12-18 | ACTUAL | 2012-12-18 | 2023-10 | 2023-10-31 | 2022-10-31 | ACTUAL | 2022-10-31 | 2016-01-27 | ACTUAL | 2016-01-27 | null | INTERVENTIONAL | SELECT-2 | null | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. | A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) | COMPLETED | null | PHASE2 | 212 | ACTUAL | AstraZeneca | null | 3 | null | null | f | null | null | null | t | null | null | null | null | null | null | null | AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure | When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure | https://astrazenecagroup-dt.pharmacm.com/DT/Home | YES | Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT01873833 | null | 2013-06-06 | 2022-11-11 | null | 2023-09-12 | 2013-06-06 | 2013-06-10 | ESTIMATED | 2023-09-12 | 2023-10-05 | ACTUAL | null | null | null | 2023-09-12 | 2023-10-05 | ACTUAL | 2013-07-29 | ACTUAL | 2013-07-29 | 2023-09 | 2023-09-30 | 2021-03-02 | ACTUAL | 2021-03-02 | 2021-03-02 | ACTUAL | 2021-03-02 | null | INTERVENTIONAL | null | null | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen | TERMINATED | null | PHASE2 | 10 | ACTUAL | University of Southern California | null | 1 | null | Insufficient accrual | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03478787 | null | 2018-03-23 | 2021-06-21 | null | 2021-06-21 | 2018-03-23 | 2018-03-27 | ACTUAL | 2021-06-21 | 2021-07-13 | ACTUAL | null | null | null | 2021-06-21 | 2021-07-13 | ACTUAL | 2018-05-08 | ACTUAL | 2018-05-08 | 2021-06 | 2021-06-30 | 2020-07-08 | ACTUAL | 2020-07-08 | 2020-07-08 | ACTUAL | 2020-07-08 | null | INTERVENTIONAL | null | null | Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis | A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy | COMPLETED | null | PHASE3 | 327 | ACTUAL | AbbVie | null | 2 | null | null | f | null | null | null | f | t | f | null | null | f | null | null | Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. | Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link. | https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html | YES | AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT04220281 | null | 2020-01-04 | null | null | 2020-02-12 | 2020-01-06 | 2020-01-07 | ACTUAL | null | null | null | null | null | null | 2020-02-12 | 2020-02-17 | ACTUAL | 2019-12-01 | ACTUAL | 2019-12-01 | 2020-02 | 2020-02-29 | 2020-02-12 | ACTUAL | 2020-02-12 | 2020-02-12 | ACTUAL | 2020-02-12 | null | INTERVENTIONAL | prop | null | Comparison Between Two Drugs (Propofol and Nitroglycerin as a Hypotensive Agents During Endoscopic Sinus Surgery | Comparison of the Hypotensive Efficacy of Propofol Infusion Versus Nitroglycerin Infusion in Functional Endoscopic Sinus Surgery | TERMINATED | null | PHASE1/PHASE2 | 40 | ACTUAL | Ain Shams University | null | 2 | null | the number of patients needed for the study have been collected | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT04251156 | null | 2020-01-30 | null | null | 2023-06-26 | 2020-01-30 | 2020-01-31 | ACTUAL | null | null | null | null | null | null | 2023-06-26 | 2023-06-27 | ACTUAL | 2020-12-08 | ACTUAL | 2020-12-08 | 2023-06 | 2023-06-30 | 2022-09-18 | ACTUAL | 2022-09-18 | 2022-08-23 | ACTUAL | 2022-08-23 | null | INTERVENTIONAL | STEP 7 | null | Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity | Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity | COMPLETED | null | PHASE3 | 375 | ACTUAL | Novo Nordisk A/S | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | http://novonordisk-trials.com | YES | According to the Novo Nordisk disclosure commitment on novonordisk-trials.com | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT02623439 | null | 2013-08-29 | null | null | 2022-07-20 | 2015-12-04 | 2015-12-07 | ESTIMATED | null | null | null | null | null | null | 2022-07-20 | 2022-07-21 | ACTUAL | 2012-07 | null | 2012-07-31 | 2022-07 | 2022-07-31 | 2022-07 | ESTIMATED | 2022-07-31 | 2022-07 | ESTIMATED | 2022-07-31 | null | INTERVENTIONAL | null | null | A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies | A Phase 2 Study of Nonmyeloablative Conditioning With Transplantation of Partially Human Leukocyte Antigen (HLA)-Mismatched Bone Marrow and Post-transplant Cyclophosphamide for Patients With Hematologic Malignancies | SUSPENDED | null | PHASE2 | 20 | ESTIMATED | University of California, San Diego | null | 1 | null | On hold for toxicitiy | f | null | null | null | t | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04063904 | null | 2019-08-13 | null | null | 2021-07-19 | 2019-08-20 | 2019-08-21 | ACTUAL | null | null | null | null | null | null | 2021-07-19 | 2021-07-23 | ACTUAL | 2019-10-16 | ACTUAL | 2019-10-16 | 2021-07 | 2021-07-31 | 2021-04-03 | ACTUAL | 2021-04-03 | 2020-04-03 | ACTUAL | 2020-04-03 | null | INTERVENTIONAL | null | null | Pilot Study of an Ambulatory Medical Abortion Service at 13-18 Weeks of Gestation in Colombia | Pilot Study of an Ambulatory Medical Abortion Service at 13-18 Weeks of Gestation in Colombia | TERMINATED | null | PHASE4 | 16 | ACTUAL | Gynuity Health Projects | null | 1 | null | Difficulties with recruitment, COVID 19 pandemic | f | null | null | null | t | f | f | null | null | f | null | null | null | null | null | null | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03548415 | null | 2018-05-22 | 2022-10-21 | 2022-03-25 | 2022-10-21 | 2018-06-05 | 2018-06-07 | ACTUAL | 2022-10-21 | 2022-11-14 | ACTUAL | 2022-03-25 | 2022-03-29 | ACTUAL | 2022-10-21 | 2022-11-14 | ACTUAL | 2018-09-13 | ACTUAL | 2018-09-13 | 2022-10 | 2022-10-31 | 2021-04-02 | ACTUAL | 2021-04-02 | 2021-02-18 | ACTUAL | 2021-02-18 | null | INTERVENTIONAL | null | The Safety Set included all participants who were randomized and received at least one dose of Study Drug. | Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands | A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 Days for 16 Weeks in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (SRL) | COMPLETED | null | PHASE2 | 43 | ACTUAL | Ionis Pharmaceuticals, Inc. | While no longer powered to assess the primary endpoint (% IGF- lowering at Day 141) in accordance with the protocol, the study did permit placebo-controlled evaluation of safety and efficacy. | 5 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT03439514 | null | 2018-02-01 | 2023-12-18 | null | 2023-12-18 | 2018-02-13 | 2018-02-20 | ACTUAL | 2023-12-18 | 2024-01-09 | ACTUAL | null | null | null | 2023-12-18 | 2024-01-09 | ACTUAL | 2018-04-17 | ACTUAL | 2018-04-17 | 2023-12 | 2023-12-31 | 2022-10-13 | ACTUAL | 2022-10-13 | 2022-10-13 | ACTUAL | 2022-10-13 | null | INTERVENTIONAL | REALM-DCM | The full analysis set (FAS) consisted of all randomized participants. | A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation | A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM) | TERMINATED | null | PHASE3 | 77 | ACTUAL | Pfizer | null | 2 | null | The Sponsor terminated the study due to futility. The decision to stop the study was not based on safety concerns. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests | YES | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT03676725 | null | 2018-09-17 | 2020-10-30 | null | 2022-09-30 | 2018-09-17 | 2018-09-19 | ACTUAL | 2021-07-07 | 2021-07-14 | ACTUAL | null | null | null | 2022-09-30 | 2022-10-06 | ACTUAL | 2019-08-14 | ACTUAL | 2019-08-14 | 2022-09 | 2022-09-30 | 2020-03-01 | ACTUAL | 2020-03-01 | 2020-03-01 | ACTUAL | 2020-03-01 | null | INTERVENTIONAL | null | null | Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD | Assessing the Frequency of Lidocaine Ineffectiveness in the General Population vs. Males With ADHD, and Females With ADHD, With or Without PMS | COMPLETED | null | EARLY_PHASE1 | 90 | ACTUAL | PhenoSolve, LLC | null | 1 | null | null | f | null | null | null | f | t | f | null | null | t | null | null | 9-12 months | Researchers | https://phenosolve.com | YES | We plan to submit for publication descriptions of what was accomplished, and the evaluations as described in the study, including the incidence of lidocaine ineffectiveness in those with ADHD and in the general population. | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT04359680 | null | 2020-04-20 | 2024-05-24 | null | 2024-06-18 | 2020-04-20 | 2020-04-24 | ACTUAL | 2024-06-18 | 2024-06-26 | ACTUAL | null | null | null | 2024-06-18 | 2024-06-26 | ACTUAL | 2020-05-13 | ACTUAL | 2020-05-13 | 2024-06 | 2024-06-30 | 2021-04-07 | ACTUAL | 2021-04-07 | 2021-04-07 | ACTUAL | 2021-04-07 | null | INTERVENTIONAL | null | Safety population consists of all subjects receiving at least one dose of study medication. | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | COMPLETED | null | PHASE3 | 1,407 | ACTUAL | Romark Laboratories L.C. | null | 2 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,021 | 1 |
NCT03358706 | null | 2017-11-27 | null | null | 2024-06-20 | 2017-11-27 | 2017-12-02 | ACTUAL | null | null | null | null | null | null | 2024-06-20 | 2024-06-21 | ACTUAL | 2018-02-02 | ACTUAL | 2018-02-02 | 2024-06 | 2024-06-30 | 2024-10-01 | ESTIMATED | 2024-10-01 | 2024-10-01 | ESTIMATED | 2024-10-01 | null | INTERVENTIONAL | null | null | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis. | SUSPENDED | null | PHASE1 | 57 | ESTIMATED | Janssen Research & Development, LLC | null | 2 | null | unavailability of probe substrates | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT03338959 | null | 2017-11-07 | 2024-06-05 | null | 2024-07-19 | 2017-11-07 | 2017-11-09 | ACTUAL | 2024-07-19 | 2024-07-23 | ACTUAL | null | null | null | 2024-07-19 | 2024-07-23 | ACTUAL | 2018-03-28 | ACTUAL | 2018-03-28 | 2024-07 | 2024-07-31 | 2023-08-04 | ACTUAL | 2023-08-04 | 2023-06-08 | ACTUAL | 2023-06-08 | null | INTERVENTIONAL | null | null | Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma | A Pilot Study of Pembrolizumab and Neoadjuvant Radiation for Large, High-Risk Soft Tissue Sarcomas | COMPLETED | null | PHASE1/PHASE2 | 27 | ACTUAL | Fred Hutchinson Cancer Center | null | 1 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT03847090 | null | 2019-02-18 | null | null | 2022-06-09 | 2019-02-19 | 2019-02-20 | ACTUAL | null | null | null | null | null | null | 2022-06-09 | 2022-06-10 | ACTUAL | 2019-08-26 | ACTUAL | 2019-08-26 | 2022-06 | 2022-06-30 | 2022-05-19 | ACTUAL | 2022-05-19 | 2022-05-19 | ACTUAL | 2022-05-19 | null | INTERVENTIONAL | URIROX-2 | null | Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria | Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2) | TERMINATED | null | PHASE3 | 92 | ACTUAL | Allena Pharmaceuticals | null | 2 | null | Interim Analysis - | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT03197935 | null | 2017-06-21 | 2021-03-29 | null | 2023-10-23 | 2017-06-21 | 2017-06-23 | ACTUAL | 2021-05-07 | 2021-06-02 | ACTUAL | null | null | null | 2023-10-23 | 2023-10-26 | ACTUAL | 2017-07-24 | ACTUAL | 2017-07-24 | 2023-10 | 2023-10-31 | 2022-09-28 | ACTUAL | 2022-09-28 | 2020-04-03 | ACTUAL | 2020-04-03 | null | INTERVENTIONAL | IMpassion031 | null | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer | A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer | COMPLETED | null | PHASE3 | 333 | ACTUAL | Hoffmann-La Roche | This study was not designed nor formally powered to demonstrate statistically significant improvements in the secondary efficacy endpoints of EFS, DFS and OS. The analyses of these secondary endpoints are descriptive in nature. | 2 | null | null | f | null | null | null | null | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT03868566 | null | 2019-03-06 | null | null | 2023-01-04 | 2019-03-06 | 2019-03-11 | ACTUAL | null | null | null | null | null | null | 2023-01-04 | 2023-01-06 | ACTUAL | 2017-08-04 | ACTUAL | 2017-08-04 | 2023-01 | 2023-01-31 | 2021-10-19 | ACTUAL | 2021-10-19 | 2021-09-22 | ACTUAL | 2021-09-22 | null | INTERVENTIONAL | null | null | An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD | An Open-Label Study to Assess the Hepatic Protection Effect of a Food Supplement Product, SNP-612, in Patients With Non-alcoholic Fatty Liver Disease | TERMINATED | null | PHASE2 | 90 | ACTUAL | Sinew Pharma Inc. | null | 2 | null | recruitment difficulties due to Covid-19 | f | null | null | null | f | f | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04218565 | null | 2019-12-08 | null | null | 2023-04-05 | 2020-01-02 | 2020-01-06 | ACTUAL | null | null | null | null | null | null | 2023-04-05 | 2023-04-07 | ACTUAL | 2020-02-15 | ACTUAL | 2020-02-15 | 2023-04 | 2023-04-30 | 2022-12-15 | ACTUAL | 2022-12-15 | 2022-12-15 | ACTUAL | 2022-12-15 | null | INTERVENTIONAL | null | null | Golimumab for the Treatment of Refractory Behcet's Uveitis | Efficacy and Safety of Golimumab in the Treatment of Refractory Uveitis in Patients With Behcet's Disease | TERMINATED | null | PHASE2 | 1 | ACTUAL | Peking Union Medical College Hospital | null | 1 | null | only one patient enrolled | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT05053737 | null | 2021-08-17 | null | null | 2024-06-21 | 2021-09-20 | 2021-09-22 | ACTUAL | null | null | null | null | null | null | 2024-06-21 | 2024-06-24 | ACTUAL | 2021-11-02 | ACTUAL | 2021-11-02 | 2024-06 | 2024-06-30 | 2024-11 | ESTIMATED | 2024-11-30 | 2023-11-24 | ACTUAL | 2023-11-24 | null | INTERVENTIONAL | null | null | Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC | Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC) | SUSPENDED | null | PHASE1 | 11 | ACTUAL | University of Colorado, Denver | null | 2 | null | Interim Analysis | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT03978156 | null | 2019-05-22 | null | null | 2021-01-21 | 2019-06-05 | 2019-06-06 | ACTUAL | null | null | null | null | null | null | 2021-01-21 | 2021-01-26 | ACTUAL | 2019-07-26 | ACTUAL | 2019-07-26 | 2021-01 | 2021-01-31 | 2021-01-01 | ACTUAL | 2021-01-01 | 2021-01-01 | ACTUAL | 2021-01-01 | null | INTERVENTIONAL | null | null | Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease | Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease | TERMINATED | null | PHASE1 | 6 | ACTUAL | Yale University | null | 2 | null | Covid-19. Relocation of trainee/investigator. Covid-19. | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | null | null | 2024-10-17 03:15:13.372527 | 2024-10-17 03:15:13.372527 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT03461861 | null | 2018-02-26 | 2022-04-28 | null | 2023-06-30 | 2018-03-05 | 2018-03-12 | ACTUAL | 2023-06-30 | 2023-07-03 | ACTUAL | null | null | null | 2023-06-30 | 2023-07-03 | ACTUAL | 2019-04-11 | ACTUAL | 2019-04-11 | 2023-06 | 2023-06-30 | 2021-03-31 | ACTUAL | 2021-03-31 | 2021-03-31 | ACTUAL | 2021-03-31 | null | INTERVENTIONAL | null | One enrolled subject did not have detectable LEV in their blood sample and was discarded in analysis | Network-Level Mechanisms for Preclinical Alzheimer's Disease Development | Network-Level Mechanisms for Preclinical Alzheimer's Disease Development | COMPLETED | null | PHASE2 | 26 | ACTUAL | Medical College of Wisconsin | 26 total patients were enrolled in the project, and 25 total patients were included in analysis. One enrolled subject did not have detectable LEV in their blood sample and was discarded in analysis. | 2 | null | null | f | null | null | null | t | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT05198362 | null | 2022-01-05 | null | null | 2022-12-09 | 2022-01-05 | 2022-01-20 | ACTUAL | null | null | null | null | null | null | 2022-12-09 | 2022-12-13 | ACTUAL | 2021-12-28 | ACTUAL | 2021-12-28 | 2022-12 | 2022-12-31 | 2022-12-09 | ACTUAL | 2022-12-09 | 2022-12-09 | ACTUAL | 2022-12-09 | null | INTERVENTIONAL | PWS | null | Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome | A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi-center, 16-week Dose Finding, Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Prader-Willi Syndrome | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Saniona | null | 4 | null | Due to financial considerations Sponsor is unable to complete the trial and assess the planned objectives/endpoints. No subjects have been randomized to treatment in the clinical trial and the decision therefore has no safety concern for patients | f | null | null | null | t | t | f | null | null | null | null | null | Following completion of Tesomet clinical development | null | null | YES | The Sponsor will consider requests from qualified researchers for access to TM006 study materials | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04367935 | null | 2020-04-26 | null | null | 2022-09-06 | 2020-04-26 | 2020-04-29 | ACTUAL | null | null | null | null | null | null | 2022-09-06 | 2022-09-07 | ACTUAL | 2021-01-01 | ACTUAL | 2021-01-01 | 2022-09 | 2022-09-30 | 2022-04-25 | ACTUAL | 2022-04-25 | 2022-04-25 | ACTUAL | 2022-04-25 | null | INTERVENTIONAL | null | null | Effect of Pentoxifylline on Endothelial Dysfunction in Patients With Acute Coronary Syndrome | Effect of Pentoxifylline on Endothelial Dysfunction in Patients With Acute Coronary Syndrome: A Pilot Study | COMPLETED | null | PHASE2/PHASE3 | 43 | ACTUAL | Ain Shams University | null | 2 | null | null | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04027946 | null | 2019-07-19 | 2023-05-24 | null | 2024-03-25 | 2019-07-19 | 2019-07-22 | ACTUAL | 2023-06-28 | 2023-07-18 | ACTUAL | null | null | null | 2024-03-25 | 2024-04-16 | ACTUAL | 2019-09-11 | ACTUAL | 2019-09-11 | 2024-03 | 2024-03-31 | 2023-12-22 | ACTUAL | 2023-12-22 | 2020-06-17 | ACTUAL | 2020-06-17 | null | INTERVENTIONAL | null | Although 3 participants were screen failures, data collected for all (6) participants enrolled is shown here. | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | TERMINATED | null | PHASE2 | 6 | ACTUAL | National Institutes of Health Clinical Center (CC) | null | 1 | null | Study was terminated due to slow accrual. | f | null | null | null | f | t | f | null | null | null | null | null | Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol Genomic Data Sharing Plan (GDS) plan for as long as database is active. | Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data are made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians. | null | YES | All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP). | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | NIH | null | null | null | null | null | null | 2,023 | 0 |
NCT03156621 | null | 2017-05-15 | 2021-04-23 | 2020-09-25 | 2021-06-07 | 2017-05-15 | 2017-05-17 | ACTUAL | 2021-06-07 | 2021-06-29 | ACTUAL | 2021-06-07 | 2021-06-29 | ACTUAL | 2021-06-07 | 2021-06-29 | ACTUAL | 2017-10-03 | ACTUAL | 2017-10-03 | 2021-06 | 2021-06-30 | 2020-02-13 | ACTUAL | 2020-02-13 | 2019-09-27 | ACTUAL | 2019-09-27 | null | INTERVENTIONAL | ODYSSEY HoFH | null | Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia | COMPLETED | null | PHASE3 | 69 | ACTUAL | Regeneron Pharmaceuticals | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT03389750 | null | 2017-12-19 | 2023-05-25 | null | 2023-08-11 | 2017-12-26 | 2018-01-04 | ACTUAL | 2023-08-11 | 2023-09-07 | ACTUAL | null | null | null | 2023-08-11 | 2023-09-07 | ACTUAL | 2018-03-15 | ACTUAL | 2018-03-15 | 2023-08 | 2023-08-31 | 2023-06-28 | ACTUAL | 2023-06-28 | 2022-06-15 | ACTUAL | 2022-06-15 | null | INTERVENTIONAL | null | Baseline demographics include all participants who were randomized/enrolled. | A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists. | A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists in Physically Dependent Opioid Users With Moderate-to-Severe Opioid Use Disorder | COMPLETED | null | PHASE2 | 16 | ACTUAL | New York State Psychiatric Institute | null | 4 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT03019588 | null | 2017-01-11 | 2022-06-21 | null | 2022-06-21 | 2017-01-11 | 2017-01-12 | ESTIMATED | 2022-06-21 | 2023-03-30 | ACTUAL | null | null | null | 2022-06-21 | 2023-03-30 | ACTUAL | 2017-02-16 | ACTUAL | 2017-02-16 | 2022-06 | 2022-06-30 | 2021-06-29 | ACTUAL | 2021-06-29 | 2021-06-29 | ACTUAL | 2021-06-29 | null | INTERVENTIONAL | null | null | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) | A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine | TERMINATED | null | PHASE3 | 94 | ACTUAL | Merck Sharp & Dohme LLC | null | 2 | null | Business Reasons | f | null | null | null | t | f | f | null | null | null | null | null | null | null | http://engagezone.msd.com/ds_documentation.php | YES | http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04091438 | null | 2019-09-13 | 2022-11-17 | null | 2022-11-17 | 2019-09-13 | 2019-09-16 | ACTUAL | 2022-11-17 | 2023-09-26 | ACTUAL | null | null | null | 2022-11-17 | 2023-09-26 | ACTUAL | 2020-01-26 | ACTUAL | 2020-01-26 | 2022-11 | 2022-11-30 | 2020-11-23 | ACTUAL | 2020-11-23 | 2020-11-19 | ACTUAL | 2020-11-19 | null | INTERVENTIONAL | null | The safety analysis set included all participants who were randomized and received at least 1 dose of the study drug. | A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia | A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia | COMPLETED | null | PHASE1 | 28 | ACTUAL | Takeda | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement. | https://vivli.org/ourmember/takeda/ | YES | Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement. | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT03508453 | null | 2018-04-16 | null | null | 2020-05-13 | 2018-04-16 | 2018-04-25 | ACTUAL | null | null | null | null | null | null | 2020-05-13 | 2020-05-15 | ACTUAL | 2019-08-15 | ESTIMATED | 2019-08-15 | 2020-05 | 2020-05-31 | 2021-12-15 | ESTIMATED | 2021-12-15 | 2021-05-15 | ESTIMATED | 2021-05-15 | null | INTERVENTIONAL | null | null | IC14 for Treatment of Amyotrophic Lateral Sclerosis | A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study of IC14 for Treatment of Patients With Rapidly Progressive Motor Neuron Disease | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Implicit Bioscience | null | 2 | null | Study will not be conducted due to lack of funding | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT02545127 | null | 2015-08-26 | 2023-11-02 | null | 2024-01-15 | 2015-09-08 | 2015-09-09 | ESTIMATED | 2024-01-15 | 2024-02-07 | ACTUAL | null | null | null | 2024-01-15 | 2024-02-07 | ACTUAL | 2021-05-28 | ACTUAL | 2021-05-28 | 2022-11 | 2022-11-30 | 2022-11-11 | ACTUAL | 2022-11-11 | 2022-11-11 | ACTUAL | 2022-11-11 | null | INTERVENTIONAL | MERMAID | null | Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely | A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Exploring the Efficacy and Safety of Intra-nasal Administration of Merotocin in Increasing Milk Production in Maternal Subjects With Preterm Delivery and Inadequate Milk Production | TERMINATED | null | PHASE2 | 4 | ACTUAL | Ferring Pharmaceuticals | null | 2 | null | The trial was prematurely terminated. Termination was not because of safety concerns but due to slow recruitment. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | INDUSTRY | null | null | null | null | null | null | 2,022 | 0 |
NCT04679818 | null | 2020-12-17 | 2024-03-01 | null | 2024-06-18 | 2020-12-17 | 2020-12-22 | ACTUAL | 2024-06-18 | 2024-06-21 | ACTUAL | null | null | null | 2024-06-18 | 2024-06-21 | ACTUAL | 2020-12-30 | ACTUAL | 2020-12-30 | 2024-05 | 2024-05-31 | 2023-01-10 | ACTUAL | 2023-01-10 | 2022-12-30 | ACTUAL | 2022-12-30 | null | INTERVENTIONAL | null | null | Postoperative Consequences of Intraoperative NOL Titration | Postoperative Consequences of Intraoperative NOL Titration | COMPLETED | null | PHASE3 | 72 | ACTUAL | The Cleveland Clinic | null | 2 | null | null | f | null | null | null | f | f | t | t | null | null | null | null | null | null | null | null | null | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | OTHER | null | null | null | null | null | null | 2,023 | 1 |
NCT04333654 | null | 2020-04-01 | null | null | 2022-04-21 | 2020-04-02 | 2020-04-03 | ACTUAL | null | null | null | null | null | null | 2022-04-21 | 2022-04-25 | ACTUAL | 2020-04-12 | ACTUAL | 2020-04-12 | 2022-04 | 2022-04-30 | 2020-05-26 | ACTUAL | 2020-05-26 | 2020-05-26 | ACTUAL | 2020-05-26 | null | INTERVENTIONAL | null | null | Hydroxychloroquine in Outpatient Adults With COVID-19 | A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19 | TERMINATED | null | PHASE1 | 8 | ACTUAL | Sanofi | null | 2 | null | Rate of enrollment too slow to allow completion in a reasonable timeframe | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | YES | Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | INDUSTRY | null | null | null | null | null | null | 2,020 | 0 |
NCT05007509 | null | 2021-08-12 | null | null | 2023-02-28 | 2021-08-12 | 2021-08-16 | ACTUAL | null | null | null | null | null | null | 2023-02-28 | 2023-03-01 | ACTUAL | 2021-08-16 | ACTUAL | 2021-08-16 | 2023-02 | 2023-02-28 | 2022-09-30 | ACTUAL | 2022-09-30 | 2021-09-30 | ACTUAL | 2021-09-30 | null | INTERVENTIONAL | null | null | Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19) | A Phase I/IIa Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers | COMPLETED | null | PHASE1/PHASE2 | 30 | ACTUAL | Laboratorios Hipra, S.A. | null | 2 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | UNDECIDED | To be decided | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | INDUSTRY | null | null | null | null | null | null | 2,022 | 1 |
NCT04560309 | null | 2020-09-07 | 2022-04-11 | null | 2023-11-09 | 2020-09-17 | 2020-09-23 | ACTUAL | 2023-11-09 | 2023-11-13 | ACTUAL | null | null | null | 2023-11-09 | 2023-11-13 | ACTUAL | 2021-01-01 | ACTUAL | 2021-01-01 | 2023-11 | 2023-11-30 | 2021-11-23 | ACTUAL | 2021-11-23 | 2021-10-30 | ACTUAL | 2021-10-30 | null | INTERVENTIONAL | null | null | Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF | Role of Glutamine as Myocardial Protector in Elective On-Pump Coronary Artery Bypass Graft Surgery With Low Ejection Fraction | COMPLETED | null | PHASE3 | 60 | ACTUAL | National Cardiovascular Center Harapan Kita Hospital Indonesia | This study has some limitations. Limitations includes the sampling time of right atrial appendage tissue which was only at 5 minutes after CPB. Right atrial appendage tissue was used for apoptotic index assessment using TUNEL staining. Right atrial appendage tissue could not be sampled at 6 hours after CPB because sternal closure was performed prior to 6 hours. | 2 | null | null | f | null | null | null | t | f | f | null | null | null | null | null | Data will be made available after publication until 36 months following article publication | Researchers needs to state their aims of analyses and provide a methodologically sound proposal. Proposals should be directed to the corresponding author. | null | YES | Individual deidentified participant data reported in this study will be made available on request after publication and ending 36 months following article publication. Researchers needs to state their aims of analyses and provide a methodologically sound proposal. Proposals should be directed to the corresponding author. | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT03364686 | null | 2017-11-22 | 2022-03-01 | null | 2022-03-29 | 2017-11-30 | 2017-12-06 | ACTUAL | 2022-03-29 | 2022-04-21 | ACTUAL | null | null | null | 2022-03-29 | 2022-04-21 | ACTUAL | 2019-09-16 | ACTUAL | 2019-09-16 | 2022-03 | 2022-03-31 | 2021-06-29 | ACTUAL | 2021-06-29 | 2021-03-02 | ACTUAL | 2021-03-02 | null | INTERVENTIONAL | null | null | Transfusion of Biotin-Labeled Red Blood Cells | Transfusion of Biotin-Labeled Red Blood Cells for the Evaluation of Genetic Factors That Contribute to Donor Differences in Red Blood Cell Storage and Post-Transfusion Red Blood Cell Recovery | TERMINATED | null | PHASE2 | 6 | ACTUAL | University of Pittsburgh | The clinical trial was terminated early due to challenges with enrollment and lack of study coordinator support. Early termination leading to small numbers of subjects analyzed. | 1 | null | Due to enrollment challenges related to COVID and lack of coordinator support | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT04983498 | null | 2021-07-20 | null | null | 2021-11-30 | 2021-07-20 | 2021-07-30 | ACTUAL | null | null | null | null | null | null | 2021-11-30 | 2021-12-15 | ACTUAL | 2021-09-01 | ESTIMATED | 2021-09-01 | 2021-11 | 2021-11-30 | 2022-01-01 | ESTIMATED | 2022-01-01 | 2021-12-01 | ESTIMATED | 2021-12-01 | null | INTERVENTIONAL | null | null | Enhanced Recovery Pathway for Endoscopy | Evaluation of an Enhanced Recovery Pathway for Endoscopy Patients Receiving Moderate Sedation | WITHDRAWN | null | PHASE4 | 0 | ACTUAL | Northwestern University | null | 2 | null | Investigator left organization before study initiated. | f | null | null | null | null | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT05431907 | null | 2022-06-08 | null | null | 2024-04-15 | 2022-06-22 | 2022-06-24 | ACTUAL | null | null | null | null | null | null | 2024-04-15 | 2024-04-17 | ACTUAL | 2022-06-29 | ACTUAL | 2022-06-29 | 2024-04 | 2024-04-30 | 2024-03-14 | ACTUAL | 2024-03-14 | 2024-03-14 | ACTUAL | 2024-03-14 | null | INTERVENTIONAL | null | null | Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis | Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis | TERMINATED | null | PHASE1/PHASE2 | 9 | ACTUAL | Enlivex Therapeutics RDO Ltd. | null | 2 | null | Sponsor decision | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT04066244 | null | 2019-08-21 | null | null | 2024-07-25 | 2019-08-21 | 2019-08-26 | ACTUAL | null | null | null | null | null | null | 2024-07-25 | 2024-07-26 | ACTUAL | 2019-12-30 | ACTUAL | 2019-12-30 | 2024-07 | 2024-07-31 | 2024-02-01 | ACTUAL | 2024-02-01 | 2024-02-01 | ACTUAL | 2024-02-01 | null | INTERVENTIONAL | null | null | Study of Safety and of the Mechanism of BLZ945 in ALS Patients | An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28 | TERMINATED | null | PHASE2 | 28 | ACTUAL | Novartis | null | 8 | null | Study terminated after assessment of potential benefit-risk from available data | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | UNDECIDED | Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com | 2024-10-17 03:21:36.842642 | 2024-10-17 03:21:36.842642 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT03931785 | null | 2019-04-22 | 2021-02-19 | null | 2021-02-19 | 2019-04-25 | 2019-04-30 | ACTUAL | 2021-02-19 | 2021-03-12 | ACTUAL | null | null | null | 2021-02-19 | 2021-03-12 | ACTUAL | 2019-05-01 | ACTUAL | 2019-05-01 | 2021-02 | 2021-02-28 | 2020-03-11 | ACTUAL | 2020-03-11 | 2020-02-26 | ACTUAL | 2020-02-26 | null | INTERVENTIONAL | null | Safety Population: all participants who received at least one dose of study drug | A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study of MD-7246 Administered Orally for 12 Weeks to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome | COMPLETED | null | PHASE2 | 515 | ACTUAL | Ironwood Pharmaceuticals, Inc. | null | 4 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-17 03:27:53.016507 | 2024-10-17 03:27:53.016507 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT03400956 | null | 2018-01-05 | 2021-03-24 | 2020-03-17 | 2022-06-29 | 2018-01-15 | 2018-01-17 | ACTUAL | 2021-04-28 | 2021-04-30 | ACTUAL | 2020-03-31 | 2020-04-06 | ACTUAL | 2022-06-29 | 2022-06-30 | ACTUAL | 2018-01-24 | ACTUAL | 2018-01-24 | 2022-06 | 2022-06-30 | 2021-06-30 | ACTUAL | 2021-06-30 | 2019-03-23 | ACTUAL | 2019-03-23 | null | INTERVENTIONAL | null | Participants in Full analysis set (FAS) was analyzed. The FAS consisted of all randomized subjects, excluding randomized subjects who did not start treatment Period 1 (never received study drug) due to the study being temporarily paused, including 96 participants. | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | A Randomized, Parallel-group, Double-blind and Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids | TERMINATED | null | PHASE3 | 103 | ACTUAL | Bayer | * The trial was terminated earlier than planned. It was sufficiently advanced to allow for meaningful analysis.~* In many subjects, follow up phase was longer than the planned one.~* Safety evaluations were not limited to the planned timepoints. | 3 | null | Due to a change in the development program, the study was closed prematurely. | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal. | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT03862053 | null | 2019-03-01 | null | null | 2020-10-07 | 2019-03-01 | 2019-03-05 | ACTUAL | null | null | null | null | null | null | 2020-10-07 | 2020-10-09 | ACTUAL | 2020-01-01 | ESTIMATED | 2020-01-01 | 2020-10 | 2020-10-31 | 2020-10-07 | ESTIMATED | 2020-10-07 | 2020-10-07 | ACTUAL | 2020-10-07 | null | INTERVENTIONAL | null | null | Manuka Eye Droops for Treatment of Allergy | A Phase 4 Study to Assess the Clinical Efficacy and Safety of Manuka Eye Drops for Treatment of Allergy | WITHDRAWN | null | PHASE4 | 0 | ACTUAL | Toyos Clinic | null | 2 | null | not enough time to complete trial;covid | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | UNDECIDED | If requested, data records without identifying patient information could be shared | 2024-10-17 03:27:53.016507 | 2024-10-17 03:27:53.016507 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03956355 | null | 2019-05-16 | 2022-06-21 | 2020-10-07 | 2022-09-16 | 2019-05-17 | 2019-05-20 | ACTUAL | 2022-09-16 | 2022-10-13 | ACTUAL | 2022-09-16 | 2022-10-13 | ACTUAL | 2022-09-16 | 2022-10-13 | ACTUAL | 2019-05-21 | ACTUAL | 2019-05-21 | 2022-09 | 2022-09-30 | 2020-05-26 | ACTUAL | 2020-05-26 | 2020-05-26 | ACTUAL | 2020-05-26 | null | INTERVENTIONAL | null | null | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) | A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults | COMPLETED | null | PHASE3 | 510 | ACTUAL | Dermavant Sciences, Inc. | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | INDUSTRY | null | null | null | null | null | null | 2,020 | 1 |
NCT04055389 | null | 2019-08-07 | null | null | 2022-02-23 | 2019-08-12 | 2019-08-13 | ACTUAL | null | null | null | null | null | null | 2022-02-23 | 2022-03-10 | ACTUAL | 2021-01-01 | ACTUAL | 2021-01-01 | 2022-02 | 2022-02-28 | 2022-02-22 | ACTUAL | 2022-02-22 | 2022-02-22 | ACTUAL | 2022-02-22 | null | INTERVENTIONAL | PiVoT | null | Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis | Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis: A Randomized, Double-blinded, Placebo - Controlled Trial (PiVoT-AC Trial) | WITHDRAWN | null | PHASE1 | 0 | ACTUAL | Milton S. Hershey Medical Center | null | 2 | null | Challenges with recruitment | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 03:27:53.016507 | 2024-10-17 03:27:53.016507 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT03770403 | null | 2018-11-16 | 2023-06-21 | null | 2023-06-21 | 2018-12-07 | 2018-12-10 | ACTUAL | 2023-06-21 | 2023-07-14 | ACTUAL | null | null | null | 2023-06-21 | 2023-07-14 | ACTUAL | 2019-03-01 | ACTUAL | 2019-03-01 | 2023-06 | 2023-06-30 | 2022-06-30 | ACTUAL | 2022-06-30 | 2022-06-23 | ACTUAL | 2022-06-23 | null | INTERVENTIONAL | ADAPT+ | The Safety Analysis set consisted of all participants who rolled over from ARGX-113-1704 and received \>=1 dose or part of a dose of efgartigimod in this study. | A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. | A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness | COMPLETED | null | PHASE3 | 151 | ACTUAL | argenx | null | 1 | null | null | t | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-16 05:34:40.88875 | 2024-10-16 05:34:40.88875 | INDUSTRY | null | NCT04777734 | APPROVED_FOR_MARKETING | null | null | null | 2,022 | 1 |
NCT03381729 | null | 2017-12-13 | 2022-05-18 | null | 2023-04-20 | 2017-12-18 | 2017-12-22 | ACTUAL | 2022-05-18 | 2023-02-16 | ACTUAL | null | null | null | 2023-04-20 | 2023-04-24 | ACTUAL | 2017-12-14 | ACTUAL | 2017-12-14 | 2023-04 | 2023-04-30 | 2021-11-18 | ACTUAL | 2021-11-18 | 2021-11-18 | ACTUAL | 2021-11-18 | null | INTERVENTIONAL | STRONG | Safety Analysis Set: All participants given an AVXS-101 intrathecal injection. Participants were analyzed according to actual dose received. | Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy | Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy | TERMINATED | null | PHASE1 | 32 | ACTUAL | Novartis | A comparison of the results from this study to the results from the natural history observational study (Pediatric Neuromuscular Clinical Research Network (PNCR), Finkel et al, 2014) are included in the Novartis Clinical Trial Results, as a historical control. These full results are available via this link: https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17933 | 3 | null | Based upon overall strategic objectives within the broader intrathecal clinical development program, Novartis Gene Therapies decided to terminate the study early. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT04212065 | null | 2019-12-19 | null | null | 2020-10-09 | 2019-12-24 | 2019-12-26 | ACTUAL | null | null | null | null | null | null | 2020-10-09 | 2020-10-14 | ACTUAL | 2020-02-21 | ACTUAL | 2020-02-21 | 2020-10 | 2020-10-31 | 2020-09-01 | ACTUAL | 2020-09-01 | 2020-09-01 | ACTUAL | 2020-09-01 | null | INTERVENTIONAL | null | null | Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women | Long Acting Subcutaneous Compared to Short Acting Sublingual Buprenorphine Administration in Pregnant and Lactating Women | WITHDRAWN | null | PHASE4 | 0 | ACTUAL | Ohio State University | null | 2 | null | closed due to new safety concerns of subcutaneous buprenorphine in pregnant patients | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-17 03:27:53.016507 | 2024-10-17 03:27:53.016507 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT03682393 | null | 2018-09-18 | null | null | 2022-03-29 | 2018-09-21 | 2018-09-24 | ACTUAL | null | null | null | null | null | null | 2022-03-29 | 2022-04-07 | ACTUAL | 2020-01-01 | ACTUAL | 2020-01-01 | 2022-03 | 2022-03-31 | 2022-12-31 | ESTIMATED | 2022-12-31 | 2022-12-31 | ESTIMATED | 2022-12-31 | null | INTERVENTIONAL | MitralPOCS | null | Post-operative Corticosteroid Treatment After Mitral Valve Surgery | Does Post-operative Corticosteroid Treatment Prevent New-onset Atrial Fibrillation After Mitral Valve Surgery? | WITHDRAWN | null | PHASE2/PHASE3 | 0 | ACTUAL | Kuopio University Hospital | null | 2 | null | the study never started | f | null | null | null | f | f | f | null | null | f | null | null | null | null | null | NO | IPD are not to be shared with other researchers. | 2024-10-17 03:27:53.016507 | 2024-10-17 03:27:53.016507 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT03782831 | null | 2018-12-19 | null | null | 2019-04-30 | 2018-12-19 | 2018-12-20 | ACTUAL | null | null | null | null | null | null | 2019-04-30 | 2019-05-02 | ACTUAL | 2018-12-11 | ACTUAL | 2018-12-11 | 2018-12 | 2018-12-31 | 2020-06-01 | ESTIMATED | 2020-06-01 | 2019-12-01 | ESTIMATED | 2019-12-01 | null | INTERVENTIONAL | null | null | TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | Transarterial Chemoembolization Plus Programmed Cell Death Protein-1 Antibody Versus Transarterial Chemoembolization Alone for Unresectable Hepatocellular Carcinoma | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Sun Yat-sen University | null | 2 | null | No participants enrolled | f | null | null | null | t | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | OTHER | null | null | null | null | null | null | 2,020 | 0 |
NCT01546753 | null | 2012-03-01 | 2021-12-03 | null | 2023-04-19 | 2012-03-06 | 2012-03-07 | ESTIMATED | 2023-04-19 | 2023-05-12 | ACTUAL | null | null | null | 2023-04-19 | 2023-05-12 | ACTUAL | 2012-04-27 | ACTUAL | 2012-04-27 | 2023-04 | 2023-04-30 | 2020-07-02 | ACTUAL | 2020-07-02 | 2015-07-02 | ACTUAL | 2015-07-02 | null | INTERVENTIONAL | WOIT | null | Walnut Oral Immunotherapy for Tree Nut Allergy | Walnut Oral Immunotherapy for Tree Nut Allergy | COMPLETED | null | PHASE1/PHASE2 | 22 | ACTUAL | University of Arkansas | Small sample size High screen failure rate High level of oropharyngeal symptoms Anxiety resulting in early termination Dosing fatigue with daily dosing Requirement for multiple food challenges in multi-tree nut assessment | 3 | null | null | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 18:03:23.937454 | 2024-10-15 18:03:23.937454 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT04996004 | null | 2021-08-02 | null | null | 2024-04-10 | 2021-08-02 | 2021-08-09 | ACTUAL | null | null | null | null | null | null | 2024-04-10 | 2024-04-11 | ACTUAL | 2021-06-22 | ACTUAL | 2021-06-22 | 2024-04 | 2024-04-30 | 2023-12-07 | ACTUAL | 2023-12-07 | 2023-12-07 | ACTUAL | 2023-12-07 | null | INTERVENTIONAL | TTI-621-03 | null | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | A Phase I/II Study of TTI-621 in Combination With Doxorubicin in Patients With Unresectable or Metastatic High-Grade Leiomyosarcoma | TERMINATED | null | PHASE2 | 75 | ACTUAL | Pfizer | null | 4 | null | Pfizer decided to terminate the study for administrative reasons. The termination was neither due to safety concerns nor a request from the regulatory authorities. | f | null | null | null | f | t | f | null | null | null | null | null | null | null | https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests | YES | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | INDUSTRY | null | null | null | null | null | null | 2,023 | 0 |
NCT04652414 | null | 2020-11-24 | null | null | 2023-02-06 | 2020-12-01 | 2020-12-03 | ACTUAL | null | null | null | null | null | null | 2023-02-06 | 2023-02-08 | ACTUAL | 2020-12-01 | ACTUAL | 2020-12-01 | 2023-02 | 2023-02-28 | 2022-07-30 | ACTUAL | 2022-07-30 | 2022-07-30 | ACTUAL | 2022-07-30 | null | INTERVENTIONAL | null | null | Corticosteroids in Community Acquired Pneumonia | Corticosteroid Treatment for Community-Acquired Pneumonia to Improve Long-term Cognition: A Pilot Randomized Controlled Trial | WITHDRAWN | null | PHASE2 | 0 | ACTUAL | Vanderbilt University Medical Center | null | 2 | null | Limited enrollment due to the COVID-19 pandemic. Sponsor withdrew funding. | f | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT04839562 | null | 2021-04-06 | 2023-12-06 | null | 2024-03-01 | 2021-04-08 | 2021-04-09 | ACTUAL | 2024-03-01 | 2024-03-04 | ACTUAL | null | null | null | 2024-03-01 | 2024-03-04 | ACTUAL | 2021-08-06 | ACTUAL | 2021-08-06 | 2024-03 | 2024-03-31 | 2023-01-27 | ACTUAL | 2023-01-27 | 2023-01-27 | ACTUAL | 2023-01-27 | null | INTERVENTIONAL | null | null | A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults | Solriamfetol for ADHD in Adults: A Double-Blind Placebo Controlled Pilot Study | COMPLETED | null | PHASE2/PHASE3 | 66 | ACTUAL | Massachusetts General Hospital | null | 2 | null | null | f | null | null | null | f | t | f | null | null | f | null | null | null | null | null | NO | null | 2024-10-15 07:02:29.301169 | 2024-10-15 07:02:29.301169 | OTHER | null | null | null | null | null | null | 2,023 | 1 |